Key clinical point: Physicians face considerable uncertainty regarding how to treat pediatric patients with MS.
Major finding: About 65% of pediatric patients with multiple sclerosis do not receive disease-modifying therapy within 1 year of diagnosis.
Study details: Retrospective, observational study of claims data from 288 patients with pediatric MS.
Disclosures: Novartis funded the study, and Dr. Deshpande, who presented the findings, and a coauthor are employees of Novartis. Other coauthors reported consulting fees from Novartis, as well as consulting fees and grant funding from other pharmaceutical companies.
Greenberg B et al. CMSC 2019, Abstract DXM02.